INNOCENTI, CHIARA
INNOCENTI, CHIARA
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY
2014 Di Gioia, M; Innocenti, C; Donnini, I; Nozzoli, C; Bosi, A; Guidi, S; Rigacci, L; Repice, A; Massacesi, L; Portaccio, E; Amato, MP; Saccardi, R
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis
2019 Mariottini, A; Filippini, S; Di Tullio, MG; Forci, B; Innocenti, C; Barilaro, A; Fani, A; Saccardi, R; Massacesi, L; Repice, AM
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis
2021 Mariottini A.; Filippini S.; Innocenti C.; Forci B.; Mechi C.; Barilaro A.; Fani A.; Carlucci G.; Saccardi R.; Massacesi L.; Repice A.M.
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis
2016 Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience
2016 Saccardi, R; Barilaro, A; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Innocenti, C; Mariottini, A; Nozzoli, C; Portaccio, E; Repice, AM; Amato, MP; Massacesi, L
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience
2016 Saccardi, R; Repice, AM; Innocenti, C; Mariottini, A; Amato, MP; Guidi, S; Fani, A; Nistri, R; Giannini, M; Portaccio, E; Barilaro, A; Nozzoli, C; Gozzini, A; Massacesi, L
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
2021 Boffa, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scime R, Frau J, Zimatore GB, Bertolotto A, ComiG, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, R. Saccardi R, Mancardi GL, and the Italian BMT-MS study group
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen
2019 Innocenti, C; Di Gioia, M; Amato, MP; Ciccone, N; Cutini, I; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Maria, RG; Saccardi, R
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports
2016 Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R
Quale strategia per la gestione dell’anemia in corso di triplice terapia anti-HCV?
2013 E.Salomoni; F.Baragli; C.Innocenti; G.Corti
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis
2018 Innocenti, C; Amato, MP; Barilaro, A; Bianchini, G; Capobianco, T; Calia, MA; Ceschini, R; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Rossolini, G; Saccardi, R
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis
2015 Mariottini, A; Innocenti, C; Repice, AM; Fani, A; Massacesi, L; Saccardi, R
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience
2017 Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY | 2014 | Di Gioia, M; Innocenti, C; Donnini, I; Nozzoli, C; Bosi, A; Guidi, S; Rigacci, L; Repice, A; Massacesi, L; Portaccio, E; Amato, MP; Saccardi, R | |
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis | 2019 | Mariottini, A; Filippini, S; Di Tullio, MG; Forci, B; Innocenti, C; Barilaro, A; Fani, A; Saccardi, R; Massacesi, L; Repice, AM | |
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis | 2021 | Mariottini A.; Filippini S.; Innocenti C.; Forci B.; Mechi C.; Barilaro A.; Fani A.; Carlucci G.; Saccardi R.; Massacesi L.; Repice A.M. | |
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis | 2016 | Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R | |
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience | 2016 | Saccardi, R; Barilaro, A; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Innocenti, C; Mariottini, A; Nozzoli, C; Portaccio, E; Repice, AM; Amato, MP; Massacesi, L | |
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience | 2016 | Saccardi, R; Repice, AM; Innocenti, C; Mariottini, A; Amato, MP; Guidi, S; Fani, A; Nistri, R; Giannini, M; Portaccio, E; Barilaro, A; Nozzoli, C; Gozzini, A; Massacesi, L | |
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis | 2021 | Boffa, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scime R, Frau J, Zimatore GB, Bertolotto A, ComiG, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, R. Saccardi R, Mancardi GL, and the Italian BMT-MS study group | |
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen | 2019 | Innocenti, C; Di Gioia, M; Amato, MP; Ciccone, N; Cutini, I; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Maria, RG; Saccardi, R | |
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports | 2016 | Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R | |
Quale strategia per la gestione dell’anemia in corso di triplice terapia anti-HCV? | 2013 | E.Salomoni; F.Baragli; C.Innocenti; G.Corti | |
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis | 2018 | Innocenti, C; Amato, MP; Barilaro, A; Bianchini, G; Capobianco, T; Calia, MA; Ceschini, R; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Rossolini, G; Saccardi, R | |
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis | 2015 | Mariottini, A; Innocenti, C; Repice, AM; Fani, A; Massacesi, L; Saccardi, R | |
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience | 2017 | Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L |